Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China
Abstract Background Chronic spontaneous urticaria (CSU) is a common inflammatory immune skin disease. It has a serious impact on the patients’ quality of life and imposes a serious financial burden on patients. The standard therapy for CSU (using antihistamines), while less costly, has limited effic...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-025-00643-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|